ENTA’s royalty per gross-sales-dollar is 50% higher in Japan than in the US and EU for GT1 patients because the approved GT1 regimen in Japan is 2-DAA (ABT-450/ABT-267 without ABT-333) rather than 3-DAA, and hence ENTA’s 10-20% tiered royalty rate in Japan is applied to 45% of ABBV’s gross sales instead of being applied to 30% of ABBV’s gross sales in the US and EU.
US/EU sales of Viekirax/Technivie for GT4 patients also have a 50% higher royalty than US/EU sales for GT1 patients, but these GT4 sales will be relatively small compared to GT1 sales in Japan.
Note: ABBV launched in Japan "very late" in 4Q15, so the numbers reported today include only a small contribution from Japan.
News 
Market Data 
Discover 
AI
